These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 23317281)

  • 1. Glutathione S-transferase P1 and DNA polymorphisms influence response to chemotherapy and prognosis of bone tumors.
    Yang LM; Li XH; Bao CF
    Asian Pac J Cancer Prev; 2012; 13(11):5883-6. PubMed ID: 23317281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of four ERCC1 and ERCC2 SNPs with survival of bone tumour patients.
    Hao T; Feng W; Zhang J; Sun YJ; Wang G
    Asian Pac J Cancer Prev; 2012; 13(8):3821-4. PubMed ID: 23098477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation of ERCC1 and ERCC2 gene polymorphisms and response to chemotherapy and overall survival in osteosarcoma.
    Zhang Q; Lv LY; Li BJ; Zhang J; Wei F
    Genet Mol Res; 2015 Sep; 14(3):11235-41. PubMed ID: 26400354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation on the DNA repaired gene polymorphisms and response to chemotherapy and overall survival of osteosarcoma.
    Ji WP; He NB
    Int J Clin Exp Pathol; 2015; 8(1):894-9. PubMed ID: 25755792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients.
    Obiedat H; Alrabadi N; Sultan E; Al Shatti M; Zihlif M
    BMC Med Genet; 2018 Jul; 19(1):112. PubMed ID: 29980176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic polymorphisms in ERCC1 and ERCC2 genes are associated with response to chemotherapy in osteosarcoma patients among Chinese population: a meta-analysis.
    Zhang H; Ge J; Hong H; Bi L; Sun Z
    World J Surg Oncol; 2017 Apr; 15(1):75. PubMed ID: 28388903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GSTP1, ERCC1 and ERCC2 polymorphisms, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in colorectal cancer in Chinese population.
    Li HY; Ge X; Huang GM; Li KY; Zhao JQ; Yu XM; Bi WS; Wang YL
    Asian Pac J Cancer Prev; 2012; 13(7):3465-9. PubMed ID: 22994779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic polymorphisms in nucleotide excision repair pathway influences response to chemotherapy and overall survival in osteosarcoma.
    Sun Y; Wu Y; Li W; Kong Z; Zou X
    Int J Clin Exp Pathol; 2015; 8(7):7905-12. PubMed ID: 26339355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single nucleotide polymorphisms in the NER pathway and clinical outcome of patients with bone malignant tumors.
    Sun XH; Hou WG; Zhao HX; Zhao YL; Ma C; Liu Y
    Asian Pac J Cancer Prev; 2013; 14(3):2049-52. PubMed ID: 23679317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between ERCC1 and ERCC2 gene polymorphisms and chemotherapy response and overall survival in osteosarcoma.
    Cao ZH; Yin HP; Jiang N; Yu B
    Genet Mol Res; 2015 Aug; 14(3):10145-51. PubMed ID: 26345951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive impact of common variations in DNA repair genes on clinical outcome of osteosarcoma.
    Bai SB; Chen HX; Bao YX; Luo X; Zhong JJ
    Asian Pac J Cancer Prev; 2013; 14(6):3677-80. PubMed ID: 23886164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ERCC polymorphisms and prognosis of patients with osteosarcoma.
    Li J; Liu S; Wang W; Zhang K; Liu Z; Zhang C; Chen S; Wu S
    Tumour Biol; 2014 Oct; 35(10):10129-36. PubMed ID: 25023406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients.
    Caronia D; Patiño-García A; Milne RL; Zalacain-Díez M; Pita G; Alonso MR; Moreno LT; Sierrasesumaga-Ariznabarreta L; Benítez J; González-Neira A
    Pharmacogenomics J; 2009 Oct; 9(5):347-53. PubMed ID: 19434073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influences of ERCC1, ERCC2, XRCC1, GSTP1, GSTT1, and MTHFR polymorphisms on clinical outcomes in gastric cancer patients treated with EOF chemotherapy.
    Liu R; Zhao X; Liu X; Chen Z; Qiu L; Geng R; Guo W; He G; Yin J; Li J; Zhu X
    Tumour Biol; 2016 Feb; 37(2):1753-62. PubMed ID: 26314858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of variation of ABCB1 and ABCC3 genotypes on the survival of bone tumor cases after chemotherapy.
    Yang J; Wang ZG; Cai HQ; Li YC; Xu YL
    Asian Pac J Cancer Prev; 2013; 14(8):4595-8. PubMed ID: 24083708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of ERCC1 and ERCC2 gene polymorphisms in patients with gastric cancer receiving platinum-based chemotherapy.
    Mo J; Luo M; Cui J; Zhou S
    Int J Clin Exp Pathol; 2015; 8(11):15065-71. PubMed ID: 26823845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive potential of ABCB1, ABCC3, and GSTP1 gene polymorphisms on osteosarcoma survival after chemotherapy.
    Liu S; Yi Z; Ling M; Shi J; Qiu Y; Yang S
    Tumour Biol; 2014 Oct; 35(10):9897-904. PubMed ID: 24996541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: a pilot study.
    Windsor RE; Strauss SJ; Kallis C; Wood NE; Whelan JS
    Cancer; 2012 Apr; 118(7):1856-67. PubMed ID: 21887680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetics of oxaliplatin as adjuvant treatment in colon carcinoma: are single nucleotide polymorphisms in GSTP1, ERCC1, and ERCC2 good predictive markers?
    Fariña Sarasqueta A; van Lijnschoten G; Lemmens VE; Rutten HJ; van den Brule AJ
    Mol Diagn Ther; 2011 Oct; 15(5):277-83. PubMed ID: 21958378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ERCC1 C8092A (rs3212986) polymorphism as a predictive marker in esophageal cancer patients treated with cisplatin/5-FU-based neoadjuvant therapy.
    Rumiato E; Cavallin F; Boldrin E; Cagol M; Alfieri R; Basso D; Castoro C; Ancona E; Amadori A; Ruol A; Saggioro D
    Pharmacogenet Genomics; 2013 Nov; 23(11):597-604. PubMed ID: 23962907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.